Arcadia Biosciences Stock Price, News & Analysis (NASDAQ:RKDA)

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month price objectives for Arcadia Biosciences' shares. Their RKDA share price targets range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 420.6% from the stock's current price.
View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts.

Arcadia Biosciences' stock was trading at $0.2710 at the start of the year. Since then, RKDA shares have increased by 963.1% and is now trading at $2.8811.
View the best growth stocks for 2023 here.

Arcadia Biosciences saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,800 shares, a decrease of 52.9% from the October 31st total of 10,200 shares. Based on an average trading volume of 16,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the shares of the company are sold short.
View Arcadia Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our RKDA earnings forecast.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced its quarterly earnings results on Thursday, November, 9th. The basic materials company reported ($1.83) earnings per share for the quarter, beating analysts' consensus estimates of ($2.67) by $0.84. The basic materials company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.89 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 77.09% and a negative net margin of 279.74%.

Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

(RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

Arcadia Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Sabby Management LLC (2.95%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela Haley, Stanley Jacot Jr and Thomas J Schaefer.
View institutional ownership trends.

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.